Aptamers for SARS-CoV-2
Creative Biolabs has successfully developed Aptamers for SARS-CoV-2 with high affinity. Creative Biolabs actively invests in aptamer development to assist researchers to better understand the characteristics of SARS-CoV-2 and drug development.
Creative Biolabs is a leading global biologics company established in the United States. With more than a decade of exploration and expansion, Creative Biolabs offers comprehensive one-stop services for Complement Therapeutics. Our project procedure can be totally designed to meet your special requirements. We will be your best partner in Complement-based Drug Discovery.
• Extensive experience and advanced biotechnologies
• Fully customizable experimental design to meet customers' needs
• Competitive price with the best quality
• Best after-sale service
The field of Complement-directed drug discovery and development has undergone a highly successful and exciting period. To accelerate the complement therapeutics, Creative Biolabs provides a full range of complement therapeutic services and complement based drug discovery services for customers. Our comprehensive complement therapeutic development services include therapeutic antibodies, serine protease inhibitors, soluble complement regulators, complement component inhibitors, as well as anaphylatoxin receptor antagonists, and other small molecules.